Drugs / CRN09682
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07129252 | Nov 2025 → Aug 2027 expected | neuroendocrine neoplasm | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-03 | Crinetics Pharmaceuticals Inc. | Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors crinetics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRN09682 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07129252 ↗ |
| Route | Intravenous | “CRN09682 intravenously” NCT07129252 ↗ |